SCHEMBL1776213

SCHEMBL1776213

COC1C[C@@H](OCc2ccccc2)[C@H](OC(=O)c2ccccc2)[C@@H](CI)O1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NT5E P21589 1/20 0.40
SLC6A2 P23975 1/20 0.36
SLC6A3 Q01959 1/20 0.36
KMT2A Q03164 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
LGALS9 O00182 1/20 0.36
LGALS1 P09382 1/20 0.36
LGALS3 P17931 1/20 0.36
LGALS7; LGALS7B P47929 1/20 0.36
PSEN1 P49768 1/20 0.36
PSEN2 P49810 1/20 0.36
APH1B Q8WW43 1/20 0.36
NCSTN Q92542 1/20 0.36
APH1A Q96BI3 1/20 0.36
PSENEN Q9NZ42 1/20 0.36
RNASE1 P07998 1/20 0.36
BCHE P06276 2/20 0.35
PTPN2 P17706 1/20 0.35
PTPN1 P18031 1/20 0.35
CHRNA7 P36544 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1776214 1.00 NT5E (0.40) NT5ESLC6A2SLC6A3KMT2ATDP1
SCHEMBL1776211 1.00 NT5E (0.40) NT5ESLC6A2SLC6A3KMT2ATDP1
SCHEMBL2911947 0.87 NT5E (0.39) NT5ESLC6A2SLC6A3KMT2ATDP1
SCHEMBL1777369 0.81 MAPT (0.39) NT5ELGALS3RNASE1
SCHEMBL1777367 0.81 MAPT (0.39) NT5ELGALS3RNASE1
SCHEMBL6306596 0.81 KMT2A (0.46) SLC6A2SLC6A3KMT2ATDP1PSEN1
SCHEMBL1775183 0.80 BCHE (0.53) NT5ELGALS3BCHEPTPN2PTPN1
SCHEMBL11374955 0.78 LGALS9 (0.40) LGALS9LGALS1LGALS3LGALS7; LGALS7BRNASE1
SCHEMBL11374956 0.78 LGALS9 (0.40) LGALS9LGALS1LGALS3LGALS7; LGALS7BRNASE1
SCHEMBL10429257 0.78 TSHR (0.51) KMT2APTPN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7943584-B2 Medicinal composition containing diabetes remedy SANKYO COMPANY, LIMITED (JP) 2011-05-17 US disclosed
CN-101367851-A Oligosaccharide derivative SANKYO CO (JP) 2009-02-18 CN disclosed
US-20080039367-A1 Medicinal Composition Containing Diabeted Remedy SANKYO COMPANY, LIMITED (JP) 2008-02-14 US disclosed
CN-100360548-C Oligosaccharide Derivatives SANKYO CO (JP) 2008-01-09 CN disclosed
EP-1792620-A1 MEDICINAL COMPOSITION CONTAINING DIABETES REMEDY Sankyo Company, Limited (JP) 2007-06-06 EP disclosed
CN-1768073-A Oligosaccharide Derivatives SANKYO CO (JP) 2006-05-03 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080039367-A1 Medicinal Composition Containing Diabeted Remedy DPP4, IAPP, AMY2A NT5E 1662/4885SLC6A2 2459/4885SLC6A3 1329/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.